Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
18F-fluciclovine PET/CT in PSMA-Low and Neuroendocrine Prostate Cancer
NCT06062745Phase 1Recruiting
- Sponsor
- Brigham and Women's Hospital
- Start
- Feb 2024
- Primary completion
- Sep 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of fluciclovine f 18 in prostate cancer (PCa) and neuroendocrine prostate cancer (NEPC), sponsored by Brigham and Women's Hospital. Primary endpoints: Fluciclovine and PSMA Uptake in PSMA Positive Tumors at 6 months and Fluciclovine and PSMA Uptake in PSMA Negative Tumors at 6 months. Started Feb 2024; status: recruiting.
02
Drugs
fluciclovine f 18
03
Conditions
prostate cancer (PCa)neuroendocrine prostate cancer (NEPC)
Beyond the preview
Go deeper on NCT06062745.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06062745.